51-43-4

51-43-4结构式

常用中文名：肾上腺素
常用英文名：Adrenaline
CAS号：51-43-4
分子式：C₉H₁₃NO₃
分子量：183.204
相关类别：原料药循环系统用药抗休克血管活性药
发布时间：2018-02-06 08:00:00
更新时间：2024-01-02 11:42:21
L-Epinephrine是由肾上腺髓质分泌的激素。它是α-adrenergic和β-adrenergic受体激动剂。
肾上腺素是一种α-肾上腺素能激动剂，β-肾上腺素能激动剂和儿茶酚胺。肾上腺素的作用机制是肾上腺素能α受体激动剂和肾上腺素能β受体激动剂。

中文名	L(-)-肾上腺素
英文名	(R)-adrenaline
中文别名	L-3,4-二羟基-alpha-((甲氨基)甲基)苄醇 L-肾上腺素盐酸盐单水合物 L-肾上腺素副肾碱 (-)-肾上腺素肾上腺素 (R)-肾上腺素肾上腺激素
英文别名	Epipen L(-)-Epinephrine 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]benzol-1,2-diol l-Epinephrine (R)-Epinephrine Lyodrin 4-[(1R)-1-hydroxy-2-(méthylamino)éthyl]benzène-1,2-diol Ana-Kit Epifrin (-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol Corisol L-Methylaminoethanolcatechol Adrine (-)-Adrenalin (−)-Adrenalin (−)-Epinephrine adrenaline R-(-)-Epinephrine L-Adrenaline (R)-(-)-adrenaline (-)-adrenaline 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]- L-Epinehphrine MFCD00002204 Bosmin L-Epinephine 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol (-)-Epinephrine (R)-adrenaline (-)-3,4-Dihydroxy-a-[(methylamino)methyl]benzyl Alcohol (S)-4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)- Adrenan EINECS 200-098-7 (-)-R-Epinephrine IOP Levo-Methylaminoethanolcatechol Adrenal Suprel (R)-(-)-Epinephrine Levoreninum Levophed (-)-3,4-dihydroxy-α-[(methylamino)methyl]-Benzyl alcohol Adrin L-Adrenalin Exadrin Adrenalin

描述	L-Epinephrine是由肾上腺髓质分泌的激素。它是α-adrenergic和β-adrenergic受体激动剂。
相关类别	信号通路 >> G 蛋白偶联受体/G 蛋白 >> 肾上腺素能受体研究领域 >> 神经疾病天然产物 >> 其他
靶点	Human Endogenous Metabolite
体内研究	与未处理的对照眼相比,将12微升体积的1％L-肾上腺素硼酸盐溶液施用于12只猴子的一只眼睛的角膜上,分别使通过虹膜和睫状体的血流减少59％和20％[ 1]。肾上腺素是一种直接作用的拟交感神经药α-肾上腺素能和β-肾上腺素能激动剂,具有环腺苷一磷酸介导的,复杂的,对许多靶器官的双向药理作用[2]。在年轻成年大鼠中,肾上腺素的内源性释放促进了对于时间相关事件的稳定记忆形成。肾上腺素通过增加调节记忆所需的血糖水平来增强年轻成年大鼠的记忆[3]。肾上腺素是心肺复苏(CPR)期间用于逆转心脏骤停的主要药物。肾上腺素通过α-1-肾上腺素能受体激动剂作用增加CPR期间的动脉血压和冠状动脉灌注[4]。
动物实验	大鼠：对于免疫组织化学实验，大鼠接受培训后立即皮下注射生理盐水（0.9％），葡萄糖（250 mg / kg）或肾上腺素（0.1 mg / kg），然后返回保持笼[3] 。
参考文献	[1]. Alm A, et al. The effect of topical l-epinephrine on regional ocular blood flow in monkeys. Invest Ophthalmol Vis Sci. 1980 May;19(5):487-91. [2]. Simons FE, et al. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol. 2004 May;113(5):837-44. [3]. Morris KA, et al. Epinephrine and glucose modulate training-related CREB phosphorylation in old rats: relationships to age-related memory impairments. Exp Gerontol. 2013 Feb;48(2):115-27. [4]. Callaway CW, et al. Epinephrine for cardiac arrest. Curr Opin Cardiol. 2013 Jan;28(1):36-42.

密度	1.3±0.1 g/cm3
沸点	413.1±40.0 °C at 760 mmHg
熔点	208-211ºC
分子式	C₉H₁₃NO₃
分子量	183.204
闪点	207.9±17.9 °C
精确质量	183.089539
PSA	72.72000
LogP	-0.63
外观性状	白色至淡黄色细结晶粉末
蒸汽压	0.0±1.0 mmHg at 25°C
折射率	1.608
储存条件	充氮密封阴凉避光保存。
分子结构	1、摩尔折射率：49.33 2、摩尔体积（cm³/mol）：142.6 3、等张比容（90.2K）：397.0 4、表面张力（dyne/cm）：59.9 5、极化率（10-24cm3）：19.55
计算化学	1.疏水参数计算参考值（XlogP）:无 2.氢键供体数量:4 3.氢键受体数量:4 4.可旋转化学键数量:3 5.互变异构体数量:10 6.拓扑分子极性表面积72.7 7.重原子数量:13 8.表面电荷:0 9.复杂度:154 10.同位素原子数量:0 11.确定原子立构中心数量:1 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1
更多	1. 性状：白色结晶性粉末。 2. 密度（g/mL,25/4℃）：未确定 3. 相对蒸汽密度（g/mL,空气=1）：未确定 4. 熔点（ºC）：211-212 5. 沸点（ºC,常压）：未确定 6. 沸点（ºC,5.2kPa）：未确定 7. 折射率：未确定 8. 闪点（ºC）：未确定 9. 比旋光度（º，C=2，0.6mol /L盐酸中）：-50～-53.5 10. 自燃点或引燃温度（ºC）：未确定 11. 蒸气压（kPa,25ºC）：未确定 12. 饱和蒸气压（kPa,60ºC）：未确定 13. 燃烧热（KJ/mol）：未确定 14. 临界温度（ºC）：未确定 15. 临界压力（KPa）：未确定 16. 油水（辛醇/水）分配系数的对数值：未确定 17. 爆炸上限（%,V/V）：未确定 18. 爆炸下限（%,V/V）：未确定 19. 溶解性：易溶于矿酸及氢氧化碱溶液，微溶于水，不溶于醇、醚、丙酮、氯仿。无气味，味苦。露置空气及见光色渐深。

Name:	Adrenaline Material Safety Data Sheet
Synonym:	Epinephrine; Adrenal; 1-Adrenaline; Adrenaso
CAS:	51-43-4

Section 1 - Chemical Product MSDS Name:Adrenaline Material Safety Data Sheet
Synonym:Epinephrine; Adrenal; 1-Adrenaline; Adrenaso

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51-43-4	1,2-benzenediol, 4-[1-hydroxy-2-(methy	100%	200-098-7

Hazard Symbols: T
Risk Phrases: 23/24/25 33

Section 3 - HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW
Toxic by inhalation, in contact with skin and if swallowed. Danger of cumulative effects.Toxic.
Potential Health Effects
Eye:
May cause eye irritation. No information regarding eye irritation and other potential effects was found.
Skin:
May cause skin irritation. No information regarding skin irritation and other potential effects was found.
Ingestion:
Causes gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
May cause respiratory tract irritation. Overexposure may cause dizziness, tremors, restlessness, rapid heart beat, increased blood pressure, hallucinations, acidosis, kidney failure.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
For small fires, use water spray, dry chemical, carbon dioxide or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Wash hands before eating. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Do not get on skin or in eyes. Do not ingest or inhale.
Storage:
Keep away from heat and flame. Store in a cool, dry, well-ventilated area away from incompatible substances. Keep containers tightly closed.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51-43-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C9H14ClNO3
Molecular Weight: 219.5559

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizers.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51-43-4: DO2625000 LD50/LC50:
CAS# 51-43-4: Skin, rat: LD50 = 62 mg/kg.
Carcinogenicity:
1,2-benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl] - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: ALKALOIDS, SOLID, NOS((-)-Adrenaline)
Hazard Class: 6.1
UN Number: 1544
Packing Group: II
IMO
Shipping Name: ALKALOIDS, SOLID, NOS((-)-Adrenaline)
Hazard Class: 6.1
UN Number: 1544
Packing Group: II
RID/ADR
Shipping Name: ALKALOIDS, SOLID, NOS((-)-Adrenaline)
Hazard Class: 6.1
UN Number: 1544
Packing group: II
USA RQ: CAS# 51-43-4: 1000 lb final RQ; 454 kg final RQ

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 23/24/25 Toxic by inhalation, in contact with skin
and if swallowed.
R 33 Danger of cumulative effects.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 51-43-4: 3
Canada
CAS# 51-43-4 is listed on Canada's DSL List.
CAS# 51-43-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51-43-4 is listed on the TSCA inventory.

SECTION 16 - ADDITIONAL INFORMATION
N/A

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DO2625000

CHEMICAL NAME :: Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, (-)-

CAS REGISTRY NUMBER :: 51-43-4

LAST UPDATED :: 199710

DATA ITEMS CITED :: 65

MOLECULAR FORMULA :: C9-H13-N-O3

MOLECULAR WEIGHT :: 183.23

WISWESSER LINE NOTATION :: QR BQ DYQ1M1 -L

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 77 mg/kg

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Behavioral - excitement Gastrointestinal - nausea or vomiting

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 43 ug/kg

TOXIC EFFECTS :: Cardiac - pulse rate increase, without fall in BP Gastrointestinal - nausea or vomiting Skin and Appendages - sweating

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 7 ug/kg

TOXIC EFFECTS :: Brain and Coverings - other degenerative changes Cardiac - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 8571 ng/kg/80M-I

TOXIC EFFECTS :: Cardiac - cardiomyopathy including infarction

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 6 ug/kg

TOXIC EFFECTS :: Cardiac - arrhythmias (including changes in conduction)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 285 ug/kg

TOXIC EFFECTS :: Cardiac - EKG changes not diagnostic of specified effects Nutritional and Gross Metabolic - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 3 mg/kg

TOXIC EFFECTS :: Vascular - contraction (isolated tissues)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 2 ug/kg

TOXIC EFFECTS :: Vascular - regional or general arteriolar constriction

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 16 ug/kg

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Cardiac - change in rate Vascular - BP lowering not characterized in autonomic section

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Multiple routes

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 625 ug/kg/I

TOXIC EFFECTS :: Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - cyanosis Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 30 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 62 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Behavioral - excitement

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 10 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - muscle weakness Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5 mg/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - respiratory stimulation

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 150 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 4 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1470 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 217 ug/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Cardiac - pulse rate increase, without fall in BP Skin and Appendages - hair

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 10 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - excitement Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 5 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 100 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Parenteral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 5 ug/kg

TOXIC EFFECTS :: Cardiac - arrhythmias (including changes in conduction)

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 20 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 500 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 30 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 4 mg/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - respiratory stimulation

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 50 ug/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - respiratory stimulation

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 800 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 100 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 12 mg/kg/4D-I

TOXIC EFFECTS :: Cardiac - changes in heart weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 50 ug/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 6 mg/kg

SEX/DURATION :: female 7-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 1 mg/kg

SEX/DURATION :: female 13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2400 ug/kg

SEX/DURATION :: female 1-6 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 10 ug/kg

SEX/DURATION :: female 20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 1 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 5 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 2 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Implant

DOSE :: 5760 ug/kg

SEX/DURATION :: female 14-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - germ cell effects (in offspring)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 16 mg/kg

SEX/DURATION :: female 7-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2400 ug/kg

SEX/DURATION :: female 6-7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 5500 ug/kg

SEX/DURATION :: female 3 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 15 mg/kg

SEX/DURATION :: male 15 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 7500 ug/kg

SEX/DURATION :: male 15 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravaginal

DOSE :: 90 ug/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2 mg/kg

SEX/DURATION :: female 7-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 2 mg/kg

SEX/DURATION :: female 7-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :: Mutation in mammalian somatic cells

TEST SYSTEM :: Rodent - mouse Lymphocyte

DOSE/DURATION :: 100 mg/L

REFERENCE :: EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 11,523,1988 *** REVIEWS *** TOXICOLOGY REVIEW CHREAY Chemical Reviews. (American Chemical Soc., Distribution Office Dept. 223, POB 57136, West End Stn., Washington, DC 20037) V.1- 1924- Volume(issue)/page/year: 9,389,1931 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,159,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - A1920 No. of Facilities: 219 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 1765 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - A1920 No. of Facilities: 327 (estimated) No. of Industries: 2 No. of Occupations: 10 No. of Employees: 18887 (estimated) No. of Female Employees: 14836 (estimated)

符号	GHS06
信号词	Danger
危害声明	H301 + H331-H310
警示性声明	P261-P280-P301 + P310-P302 + P350-P310
个人防护装备	Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
危害码 (欧洲)	T:Toxic
风险声明 (欧洲)	R23/24/25;R33;R36/37/38;R52/53
安全声明 (欧洲)	S23-S26-S36/37/39-S45-S61
危险品运输编码	UN 2811
WGK德国	3
RTECS号	DO2625000
包装等级	II
危险类别	6.1
海关编码	2922509090

104819-58-1

~52%

51-43-4

文献：Muller; Keil; Gerhard Tetrahedron, 1986 , vol. 42, # 5 p. 1529 - 1532

87-69-4

329-65-7

51-43-4

文献：WOCKHARDT RESEARCH CENTRE; YADAV, RAMPRASAD; SHAIKH, ZAKIR GAFOOR; NASIR ALI, SHAFAKAT ALI; MERWADE, ARVIND; SIDDIQUI MOHAMMAD, JAWEED MUKARRAM Patent: WO2009/4593 A2, 2009 ; Location in patent: Page/Page column 7 ;

41787-64-8

~97%

51-43-4

文献：Singer, Robert A.; Carreira, Erick M. Tetrahedron Letters, 1997 , vol. 38, # 6 p. 927 - 930

62-13-5

51-43-4

文献：Muller; Keil; Gerhard Tetrahedron, 1986 , vol. 42, # 5 p. 1529 - 1532

104819-56-9

51-43-4

文献：Muller; Keil; Gerhard Tetrahedron, 1986 , vol. 42, # 5 p. 1529 - 1532

120-14-9

51-43-4

文献：Singer, Robert A.; Carreira, Erick M. Tetrahedron Letters, 1997 , vol. 38, # 6 p. 927 - 930

188415-28-3

51-43-4

文献：Singer, Robert A.; Carreira, Erick M. Tetrahedron Letters, 1997 , vol. 38, # 6 p. 927 - 930

87-69-4

99-45-6

51-43-4

文献：Ges. f. Chem. Ind. Basel Patent: DE505460 ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 2098

上游产品 7
87-69-4 329-65-7 41787-64-8 62-13-5
104819-56-9 120-14-9 99-45-6
下游产品 10
74-89-5 64-18-6 144-62-7 329-65-7
99-50-3 120-80-9 121-33-5 93-07-2
75-50-3 26405-77-6

海关编码	2922509090
中文概述	2922509090. 其他氨基醇酚、氨基酸酚及其他含氧基氨基化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件：AB. 最惠国关税:6.5%. 普通关税:30.0%
申报要素	品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装
监管条件	A.入境货物通关单 B.出境货物通关单
检验检疫	R.进口食品卫生监督检验 S.出口食品卫生监督检验
Summary	2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

51-43-4	54-06-8
59-42-7	80-49-9
26405-77-6	55-31-2
154-86-9	94-07-5
5794-08-1	51-41-2
1185133-02-1	1158522-08-7
36946-00-6	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1260786-68-2